8-K: enGene Holdings Inc. Enters $100 Million At-the-Market Offering Agreement with Jefferies LLC

enGene Holdings Inc. has entered into an agreement with Jefferies LLC to potentially sell up to $100 million of its common shares through an at-the-market offering.

Summary

• enGene Holdings Inc. has signed an Open Market Sale Agreement with Jefferies LLC, allowing the company to offer and sell common shares up to a total of $100 million.
• Jefferies will act as a sales agent, using commercially reasonable efforts to sell the shares based on enGene's instructions, including any price or time limits.
• The shares will be sold through an at-the-market offering, as defined by SEC rules, and no shares will be offered or sold in Canada.
• Jefferies will receive a commission of up to 3.0% of the gross proceeds from the share sales, and enGene will also cover certain expenses.
• The offering is made under an existing registration statement and will be conducted through a prospectus supplement dated December 20, 2024.
• enGene is not obligated to sell any shares under this agreement, and the agreement can be terminated by either party.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive. It outlines a capital raising activity which is a normal business function. The terms are standard and there are no indications of any issues.

Positives

• The agreement provides enGene with a flexible way to raise capital.
• The at-the-market offering allows the company to sell shares gradually, potentially minimizing market impact.
• The company is not obligated to sell any shares, giving them control over the timing and amount of the offering.

Negatives

• The company will incur commission costs of up to 3.0% of the gross proceeds.
• The company will also be responsible for certain expenses related to the offering.
• The offering could potentially dilute existing shareholders if a large number of shares are sold.

Risks

• There is no guarantee that enGene will be able to sell all $100 million of shares.
• The market price of the shares could be negatively impacted by the offering.
• The company's ability to raise capital through this method depends on market conditions and investor demand.

Future Outlook

The company may offer and sell shares from time to time through Jefferies, but is not obligated to do so. The offering will terminate upon the termination of the Sale Agreement.

Management Comments

• The document includes a signature from Lee Giguere, Chief Legal Officer, on behalf of enGene Holdings Inc.

Industry Context

At-the-market offerings are a common method for publicly traded companies to raise capital, particularly in the biotechnology sector. This allows companies to access funding without the need for a large, dilutive secondary offering.

Comparison to Industry Standards

• The 3% commission is within the typical range for at-the-market offerings.
• The $100 million offering size is significant but not unusual for a company of enGene's size and stage.
• Other biotech companies such as Xencor and Iovance have used similar at-the-market offerings to raise capital.

Stakeholder Impact

• Shareholders may experience dilution if a large number of shares are sold.
• The company will have access to additional capital to fund its operations.
• The offering could potentially impact the share price.

Next Steps

• enGene may issue instructions to Jefferies to sell shares from time to time.
• Jefferies will attempt to sell the shares based on enGene's instructions.
• The offering will continue until the $100 million limit is reached or the agreement is terminated.

Key Dates

Keywords

at-the-market offering, common shares, capital raise, Jefferies LLC, equity financing, securities, sale agreement